AU7761594A - Polyethylene glycols - Google Patents

Polyethylene glycols

Info

Publication number
AU7761594A
AU7761594A AU77615/94A AU7761594A AU7761594A AU 7761594 A AU7761594 A AU 7761594A AU 77615/94 A AU77615/94 A AU 77615/94A AU 7761594 A AU7761594 A AU 7761594A AU 7761594 A AU7761594 A AU 7761594A
Authority
AU
Australia
Prior art keywords
polyethylene glycols
glycols
polyethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU77615/94A
Other versions
AU671045B2 (en
Inventor
John Hakimi
Patricia Kilian
Perry Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US67400191A priority Critical
Priority to US767000 priority
Priority to US07/767,000 priority patent/US5595732A/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU7761594A publication Critical patent/AU7761594A/en
Priority to US674001 priority
Application granted granted Critical
Publication of AU671045B2 publication Critical patent/AU671045B2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27101069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU7761594(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Anticipated expiration legal-status Critical
Application status is Ceased legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/964Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer
    • Y10S530/816Attached to the carrier via a bridging agent
AU77615/94A 1991-03-25 1994-11-01 Polyethylene glycols Ceased AU671045B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US67400191A true 1991-03-25 1991-03-25
US767000 1991-09-27
US07/767,000 US5595732A (en) 1991-03-25 1991-09-27 Polyethylene-protein conjugates
US674001 1996-07-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU13160/92A Division AU657311B2 (en) 1991-03-25 1992-03-24 Polyethylene protein conjugates

Publications (2)

Publication Number Publication Date
AU7761594A true AU7761594A (en) 1995-01-12
AU671045B2 AU671045B2 (en) 1996-08-08

Family

ID=27101069

Family Applications (2)

Application Number Title Priority Date Filing Date
AU13160/92A Ceased AU657311B2 (en) 1991-03-25 1992-03-24 Polyethylene protein conjugates
AU77615/94A Ceased AU671045B2 (en) 1991-03-25 1994-11-01 Polyethylene glycols

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU13160/92A Ceased AU657311B2 (en) 1991-03-25 1992-03-24 Polyethylene protein conjugates

Country Status (32)

Country Link
US (7) US5595732A (en)
EP (1) EP0510356B1 (en)
JP (1) JP2637010B2 (en)
KR (1) KR920018079A (en)
CN (2) CN1038035C (en)
AT (1) AT176159T (en)
AU (2) AU657311B2 (en)
BG (1) BG60800B2 (en)
BR (1) BR9201015A (en)
CA (1) CA2063886C (en)
CS (1) CS87192A3 (en)
CY (1) CY2169B1 (en)
DE (2) DE69228269D1 (en)
DK (1) DK0510356T3 (en)
EE (1) EE9400356A (en)
ES (1) ES2128329T3 (en)
FI (2) FI107927B (en)
GR (1) GR3030049T3 (en)
HU (2) HUT60512A (en)
IE (1) IE920936A1 (en)
IL (1) IL101348D0 (en)
IS (1) IS3824A (en)
MW (1) MW1892A1 (en)
MX (1) MX9201298A (en)
MY (1) MY131095A (en)
NO (1) NO921142L (en)
NZ (2) NZ248022A (en)
OA (1) OA9760A (en)
RO (1) RO109543B1 (en)
SI (1) SI9210294A (en)
ZA (1) ZA9202110B (en)
ZW (1) ZW4392A1 (en)

Families Citing this family (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
AU5006993A (en) * 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
AU8052194A (en) * 1993-10-20 1995-05-08 Enzon, Inc. 2'- and/or 7- substituted taxoids
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
KR960705579A (en) * 1993-11-10 1996-11-08 에릭에스. 딕커 An improved interferon-polymer conjugate (Improved interferon polymer conjugates)
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
DE19512484A1 (en) * 1995-04-04 1996-10-17 Bayer Ag Carbohydrate-modified cytostatics
DE19514087A1 (en) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Conjugate of an active agent, a polyether, and optionally, a non regarded as foreign, native protein
ES2093593T1 (en) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteins obese (ob) recombinants.
ZA9603530B (en) * 1995-05-05 1996-11-05 Hoffmann La Roche Recombinant obese (ob) proteins
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
DE69632062T2 (en) 1995-11-02 2004-11-18 Schering Corp. Continuous low-dose cytokine-infusion therapy
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO1998035551A1 (en) 1997-02-13 1998-08-20 Lxr Biotechnology Inc. Organ preservation solution
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
AT258599T (en) 1997-02-21 2004-02-15 Genentech Inc Antibody fragment-polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US7005504B2 (en) * 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
FR2774687B1 (en) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides containing a fragment of interferon gamma, and their use in pharmaceutical compositions
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
PT956861E (en) 1998-05-15 2002-08-30 Schering Corp Combined therapy understanding ribavirin and alpha interference in patients without previous antiviral treatment having chronic infection by hepatitis c virus
CA2334267C (en) * 1998-06-08 2009-02-17 F. Hoffmann-La Roche Ag Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
ES2630278T3 (en) 1998-10-16 2017-08-21 Biogen Ma Inc. Interferon beta-1a polymer conjugates and uses thereof
ES2265693T3 (en) 1998-10-16 2007-02-16 Biogen Idec Ma Inc. Fusion proteins with interferon-beta and uses.
TWI257394B (en) * 1998-10-23 2006-07-01 Kirin Amgen Inc Thrombopoietic compounds
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
CA2303992A1 (en) 1999-04-08 2000-10-08 Schering Corporation Melanoma therapy
PE02882001A1 (en) 1999-07-02 2001-03-07 Hoffmann La Roche Erythropoietin derivatives
AU4934299A (en) * 1999-07-15 2001-02-05 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
HU0203409A3 (en) 1999-11-12 2005-06-28 Maxygen Holdings Ltd Redwood C Interferon gamma conjugates
US7230081B1 (en) 1999-11-12 2007-06-12 Maxygen Holdings, Ltd. Interferon gamma conjugates
EP1250154B1 (en) 2000-01-10 2009-07-01 Maxygen Holdings Ltd G-csf conjugates
EP2319541A1 (en) 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US7309694B2 (en) * 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (en) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Cytokines modified for use in cancer therapy.
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US7030218B2 (en) * 2000-09-08 2006-04-18 Gryphon Therapeutics Pseudo native chemical ligation
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
US20040058865A1 (en) * 2001-11-26 2004-03-25 Danishefsky Samuel J Homing peptide multimers, their preparation and uses
WO2002074806A2 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
DE60223047T2 (en) 2001-08-22 2008-07-24 Bioartificial Gel Technologies Inc., Montreal Process for preparing activated polyethylene glycols
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
JP2005511553A (en) 2001-11-01 2005-04-28 サイクローン・ファーマシューティカルズ・インコーポレイテッドSciClone Pharmaceuticals,Inc. Thymosin alpha 1 peptide / polymer complex
US6916962B2 (en) * 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) * 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
KR100488351B1 (en) * 2001-12-11 2005-05-11 선바이오(주) Novel polyethylene glycol-propionaldehyde derivatives
US7041855B2 (en) * 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
KR100888371B1 (en) 2002-01-17 2009-03-13 동아제약주식회사 Antivirus agent comprising bridged co-polymer derivatives and interferon complexes
ME00239B (en) 2002-01-18 2011-05-10 Biogen Ma Inc Polyalkylene polymer compounds and uses thereof
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
ES2363205T3 (en) 2002-06-21 2011-07-26 Novo Nordisk Health Care Ag Pegilated factor vii glicoforms.
WO2004002999A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
CA2491178A1 (en) * 2002-07-03 2004-01-15 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
ES2601143T3 (en) 2002-07-19 2017-02-14 Omeros Corporation Biodegradable triblock copolymers, synthesis methods thereof, and hydrogels and biomaterials prepared therefrom.
EP1382352A1 (en) 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein conjugates and the use thereof
CA2492775C (en) * 2002-07-24 2011-06-21 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
US7563507B2 (en) * 2002-08-16 2009-07-21 University Of Massachusetts Pyridine and related ligand compounds, functionalized nanoparticulate composites and methods of preparation
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7217845B2 (en) * 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
DK1667708T5 (en) * 2002-12-26 2012-11-12 Mountain View Pharmaceuticals Polyethylene glycol conjugates of interferon-beta-1b with increased biological potency in vitro
RS20050501A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US20040176655A1 (en) * 2003-02-05 2004-09-09 Ayoub Paul Marie Methods of preparing branched alkyl aromatic hydrocarbons
US20050079155A1 (en) * 2003-03-20 2005-04-14 Xencor, Inc. Generating protein pro-drugs using reversible PPG linkages
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
JP4958158B2 (en) 2003-05-30 2012-06-20 ギリアド ファーマセット エルエルシー Modified fluorinated nucleoside analogues
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
CN102516386A (en) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21 derivatives
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
NZ586034A (en) * 2004-02-02 2011-10-28 Ambrx Inc Modified human growth hormone polypeptides and their uses
CN1914223B (en) 2004-02-02 2012-02-29 Ambrx公司 Modified human interferon polypeptides and their uses
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
US7318918B2 (en) * 2004-05-19 2008-01-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US20060194726A1 (en) * 2004-05-25 2006-08-31 Rueger David C Methods of treating cartilage defects
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
JP2008503217A (en) * 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド Novel antigen-binding polypeptides and their use
MXPA06015234A (en) * 2004-06-30 2007-11-22 Nektar Therapeutics Al Corp Polymer-factor ix moiety conjugates.
US8143380B2 (en) * 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
US7605123B2 (en) 2004-07-19 2009-10-20 Biocon Ltd. Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof
CN101023094B (en) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
WO2006091231A2 (en) * 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
BRPI0513332A (en) * 2004-08-12 2008-05-06 Schering Corp stable pegylated interferon formulation
JP5001842B2 (en) * 2004-09-14 2012-08-15 ギリアド ファーマセット エルエルシー Production of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and derivatives thereof
CN103290084A (en) 2004-12-22 2013-09-11 Ambrx公司 Method for expression and purification of recombinant human growth hormone
BRPI0519430A2 (en) 2004-12-22 2009-02-10 Ambrx Inc modified human growth hormone
BRPI0519568A2 (en) * 2004-12-22 2009-01-27 Ambrx Inc aminoacyl trna synthetase compositions and their uses
CA2594561C (en) 2004-12-22 2014-12-23 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
WO2006071801A2 (en) * 2004-12-27 2006-07-06 Baxter International Inc Polymer-von willebrand factor-conjugates
KR20070099013A (en) 2005-01-31 2007-10-08 주식회사 에펙타 세포연구소 Immunopotentiating agent
CA2607651A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
US20070015701A1 (en) * 2005-06-01 2007-01-18 Samuel Zalipsky Macromolecular conjugates of bone morphogenetic protein-7
SG165353A1 (en) * 2005-06-03 2010-10-28 Ambrx Inc Improved human interferon molecules and their uses
RU2427372C2 (en) 2005-06-17 2011-08-27 Новартис Аг Application of sangliferin for treating hepatitis c virus
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
CN101500606B (en) * 2005-06-24 2013-12-04 杜克大学 A direct drug delivery system based on thermally responsive biopolymers
AU2005335491B2 (en) 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
US20070123646A1 (en) * 2005-09-13 2007-05-31 Lele Bhalchandra S Protein-polymer conjugates and synthesis thereof
EP1776963A1 (en) * 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
KR101379071B1 (en) * 2005-11-08 2014-03-28 암브룩스, 인코포레이티드 Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
CN106443006A (en) 2005-11-16 2017-02-22 Ambrx公司 Methods and compositions comprising non-natural amino acids
NZ595303A (en) * 2005-12-14 2013-03-28 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
JP5046030B2 (en) 2006-01-12 2012-10-10 北里第一三共ワクチン株式会社 Oral composition containing interferon alpha
WO2007088051A2 (en) 2006-01-31 2007-08-09 Bayer Schering Pharma Aktiengesellschaft Modulation of mdl-1 activity for treatment of inflammatory disease
DE602007008627D1 (en) * 2006-02-14 2010-10-07 Genetix Ltd Cell culture medium
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
WO2007133865A2 (en) 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors an their uses
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
RU2008145084A (en) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Analogues of factor ix having a long-term half-time in vivo
EP1897557A1 (en) * 2006-09-07 2008-03-12 Helmholtz-Zentrum für Infektionsforschung GmbH Use of glycolipids as adjuvants
EP2064333B1 (en) * 2006-09-08 2014-02-26 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
CN106008699A (en) 2006-09-08 2016-10-12 Ambrx公司 Modified human plasma polypeptide or Fc scaffolds and their uses
CA2662753C (en) * 2006-09-08 2016-02-23 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
MX2010005317A (en) 2007-11-20 2010-06-02 Ambrx Inc Modified insulin polypeptides and their uses.
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
TWI541020B (en) 2008-04-17 2016-07-11 Baxalta Inc Bioactive peptides
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CN105727261A (en) 2008-06-27 2016-07-06 杜克大学 Therapeutic agents comprising elastic peptides
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
CN101671390B (en) 2008-09-10 2012-10-03 北京四环制药有限公司 Human interferon alpha derivatives and preparation and use of pegylated products thereof
CA2738033A1 (en) 2008-09-26 2010-04-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
EP2671888A1 (en) 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-cyclic nucleoside phosphate analogues
CN102695513A (en) 2008-12-23 2012-09-26 吉利德制药有限责任公司 Nucleoside phosphoramidates
KR20110098849A (en) 2008-12-23 2011-09-01 파마셋 인코포레이티드 Nucleoside analogs
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
CN101870728A (en) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 Novel Exendin variant and conjugate thereof
TWI583692B (en) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
AR080870A1 (en) 2010-03-31 2012-05-16 Pharmasset Inc Propanoate crystal (s) -isopropyl 2 - (((s) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydro-1 (2H) -yl) -4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino, pharmaceutical compositions containing them and use thereof in treating viral infections, in particul
EP2437768B1 (en) * 2009-06-04 2016-08-10 The University of North Carolina At Chapel Hill Compounds and methods for treating bone disorders and controlling weight
US20110097302A1 (en) * 2009-07-16 2011-04-28 Ta Tung Yuan Il-1ra-polymer conjugates
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
KR101887009B1 (en) * 2009-08-14 2018-08-09 파세비오 파마수티컬스 인코포레이티드 Modified Vasoactive Intestinal Peptide
US8475652B2 (en) 2009-10-19 2013-07-02 Jan A. K. Paul Method for purification of uncatalyzed natural fuels from metal ions by means of at least one hemeprotein and use of the at least on hemeprotein
US8822496B2 (en) 2009-10-30 2014-09-02 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
JP6148013B2 (en) 2010-03-05 2017-06-14 リグショスピタレト Chimera inhibitor molecule of complement activation
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
JP2013529627A (en) 2010-06-24 2013-07-22 パンメド リミテッド Treatment of hepatitis C virus-related disease using hydroxychloroquine or a combination of hydroxychloroquine and an antiviral agent
NZ607069A (en) 2010-08-17 2014-10-31 Ambrx Inc Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
KR20140019284A (en) 2010-09-03 2014-02-14 아카데미아 시니카 Anti-c-met antibodies and methods of use thereof
AU2011311706B2 (en) 2010-10-05 2015-11-12 Debiopharm S.A. New treatments of Hepatitis C virus infection
KR20130120481A (en) 2010-10-08 2013-11-04 노파르티스 아게 Vitamin e formulations of sulfamide ns3 inhibitors
KR20130116888A (en) * 2010-11-12 2013-10-24 넥타르 테라퓨틱스 Conjugates of an il-2 moiety and a polymer
AU2011334984A1 (en) 2010-11-30 2013-07-04 Novartis Ag New treatments of Hepatitis C virus infection
ES2716158T3 (en) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleotides for the treatment of hepatitis C
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
RU2013148539A (en) 2011-03-31 2015-05-10 Новартис Аг Alisporivir for treatment of hepatitis c virus infection
RS53911B1 (en) 2011-04-01 2015-08-31 Novartis Ag Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
MX2013011941A (en) 2011-04-13 2014-05-28 Debiopharm Int Sa Treatment of hepatitis c virus infection with alisporivir.
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
KR20140054009A (en) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 Relaxin fusion polypeptides and uses thereof
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20140228281A1 (en) 2011-09-27 2014-08-14 Novartis Ag Alisporivr for treatment of hepatitis c virus infection
US8767214B2 (en) 2011-10-06 2014-07-01 Nordson Corporation Powder flow detection
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
WO2013161895A1 (en) * 2012-04-25 2013-10-31 第一三共株式会社 Bone repair promoter
WO2013185115A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CA2878642A1 (en) 2012-07-19 2014-01-23 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
EP3007726A1 (en) 2013-06-10 2016-04-20 Ipierian, Inc. Methods of treating a tauopathy
DK2890402T3 (en) 2012-08-31 2019-07-15 Sutro Biopharma Inc Modified amino acids including an azidog group
CA2891974A1 (en) 2012-11-21 2014-05-30 The Governors Of The University Of Alberta Immunomodulatory peptides and methods of use thereof
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
ES2658039T3 (en) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
EP3055298A1 (en) 2013-10-11 2016-08-17 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
BR112016010454A2 (en) 2013-11-27 2017-12-05 Ipierian Inc methods to treat a taupathy
EP3183264A1 (en) 2014-08-19 2017-06-28 Biogen MA Inc. Pegylation method
KR20170070227A (en) 2014-10-24 2017-06-21 브리스톨-마이어스 스큅 컴퍼니 Modified fgf-21 polypeptides and uses thereof
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
TW201837051A (en) 2017-02-08 2018-10-16 美商必治妥美雅史谷比公司 Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (en) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (en) * 1967-12-20 1972-03-06 Pharmacia Ab
DK132327A (en) * 1968-07-16
BE758425A (en) * 1969-12-02 1971-04-16 Baxter Laboratories Inc Streptokinase linked chemically to a matrix of carbohydrate (
DE2247163A1 (en) * 1972-09-26 1974-03-28 Merck Patent Gmbh Traegermatrix for fixation of biologically active materials and methods for their production
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4094744A (en) * 1976-11-18 1978-06-13 W. R. Grace & Co. Water-dispersible protein/polyurethane reaction product
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
IT1107772B (en) * 1977-08-22 1985-11-25 Cancer Res Inst Royal Process for the production of complex macromolecular product obtained and pharmaceutical compositions containing it as an active ingredient
JPS5717001B2 (en) * 1979-02-19 1982-04-08
JPS6023084B2 (en) * 1979-07-11 1985-06-05 Ajinomoto Kk
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS6222559B2 (en) * 1981-12-04 1987-05-19 Stanley Electric Co Ltd
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
JPS6262153B2 (en) * 1983-11-01 1987-12-24 Kagaku Oyobi Ketsusei Ryoho Kenkyusho
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0229108B1 (en) * 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4818769A (en) * 1985-09-20 1989-04-04 Cetus Corporation Method of controlling stress-related disease in livestock by administration of human IL-2
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5034514A (en) * 1986-03-17 1991-07-23 Cetus Corporation Novel cross-linking agents
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
JPH0443882Y2 (en) * 1986-06-23 1992-10-16
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
EP0304311A1 (en) * 1987-08-21 1989-02-22 The Wellcome Foundation Limited Complex of polyethylene glycol and tissue plasminogen activator
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
WO1990005534A1 (en) * 1988-11-23 1990-05-31 Genentech, Inc. Polypeptide derivatives
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2247656T3 (en) * 1989-04-19 2006-03-01 Enzon, Inc. A process for forming a modified polypeptide comprising a polypeptide and polyalkylene oxide.
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
CA2067224C (en) * 1989-12-01 2001-02-13 Manfred Kurfuerst Hirudin/polyalkylene glycol conjugates
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates

Also Published As

Publication number Publication date
OA9760A (en) 1993-11-30
BR9201015A (en) 1992-11-24
SI9210294A (en) 1995-10-31
CY2169B1 (en) 2002-08-23
FI921267A (en) 1992-09-26
US5834594A (en) 1998-11-10
ZA9202110B (en) 1992-11-25
HUT60512A (en) 1992-09-28
JP2637010B2 (en) 1997-08-06
US5792834A (en) 1998-08-11
EE9400356A (en) 1996-04-15
MW1892A1 (en) 1994-01-12
FI921267A0 (en) 1992-03-24
IL101348D0 (en) 1992-11-15
AU657311B2 (en) 1995-03-09
CN1108814C (en) 2003-05-21
IS3824A (en) 1992-09-26
AU671045B2 (en) 1996-08-08
AU1316092A (en) 1992-10-01
AT176159T (en) 1999-02-15
ZW4392A1 (en) 1992-09-23
DK0510356T3 (en) 1999-09-13
CS87192A3 (en) 1992-10-14
US5595732A (en) 1997-01-21
RO109543B1 (en) 1995-03-30
CN1038035C (en) 1998-04-15
GR3030049T3 (en) 1999-07-30
US5849860A (en) 1998-12-15
DE69228269T2 (en) 1999-07-08
ES2128329T3 (en) 1999-05-16
CN1175465A (en) 1998-03-11
US5747646A (en) 1998-05-05
BG60800B2 (en) 1996-03-29
US5539063A (en) 1996-07-23
CA2063886C (en) 2002-08-20
FI107927B (en) 2001-10-31
NO921142L (en) 1992-09-28
HU9200955D0 (en) 1992-05-28
FI921267D0 (en)
CN1065465A (en) 1992-10-21
EP0510356B1 (en) 1999-01-27
US5559213A (en) 1996-09-24
FI107927B1 (en)
EP0510356A1 (en) 1992-10-28
NZ242084A (en) 1993-12-23
IE920936A1 (en) 1992-10-07
NO921142D0 (en) 1992-03-24
FI20011554A (en) 2001-07-17
KR920018079A (en) 1992-10-21
DE69228269D1 (en) 1999-03-11
CA2063886A1 (en) 1992-09-26
MX9201298A (en) 1992-10-01
MY131095A (en) 2007-07-31
HU211945A9 (en) 1996-01-29
JPH05117300A (en) 1993-05-14
NZ248022A (en) 1993-12-23

Similar Documents

Publication Publication Date Title
AU657350B2 (en) Heterocyclic compounds
AU654316B2 (en) Osteogenic factor
AU635147B2 (en) Transmitter
AU684570B2 (en) Ultramulsions
AU639126B2 (en) Oxorapamycin
AU695850B2 (en) Poly-beta -1-4-N-acetylglucosamine
AU658898B2 (en) Substituted 3-aminoquinuclidines
AU647780B2 (en) CTMP-process
AU668526B2 (en) Enzyme-orthokeratology
AU643989B2 (en) Container
AU2188992A (en) Azanorbornane derivatives
AU2525192A (en) Alkylbisacylphosphine oxides
AU2056992A (en) Heterocyclic compounds
AU1576992A (en) Fragrance-emitting container
AU2618292A (en) Novel 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
AU5595194A (en) Custom-fitting articles
AU5783294A (en) Azacyclohexapeptide compounds
AU1434192A (en) Article
AU1317795A (en) Machine-tool
AU3172893A (en) 5-O-desosaminylerythronolide derivatives
AU7178694A (en) Absorbent articles
AU5515494A (en) Absorbent articles
AU3271393A (en) An absorbent article
AU6826494A (en) Absorbent article
AU2996992A (en) An absorbent article